1. Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
- Author
-
Alric, Christophe, Hervé-Aubert, Katel, Aubrey, Nicolas, Melouk, Souad, Lajoie, Laurie, Même, William, Même, Sandra, Courbebaisse, Yann, Ignatova, Anastasia A., Feofanov, Alexey V., Chourpa, Igor, Allard-Vannier, Emilie, Nanomédicaments et Nanosondes, EA 6295 (NMNS), Université de Tours, Infectiologie Santé Publique (ISP-311), Institut National de la Recherche Agronomique (INRA)-Université de Tours, Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] (GICC EA 7501), Centre de biophysique moléculaire (CBM), Université d'Orléans (UO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), IDPS-Bertin Pharma, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (IBCh RAS), Russian Academy of Sciences [Moscow] (RAS), Lomonosov Moscow State University (MSU), Université de Tours-Institut National de la Recherche Agronomique (INRA), Université de Tours (UT), Infectiologie et Santé Publique (UMR ISP), Institut National de la Recherche Agronomique (INRA)-Université de Tours (UT), Université d'Orléans (UO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), French Higher Education and Research ministry under the program 'Investissements d’avenir' Grant Agreement: LabEx MAbImprove ANR-10-LABX-53–01, Russian Foundation for Basic Research (grant 16-54-76013) French Ministry of National Education, Higher Education and Research (MENESR, Project No. 321 MINERVA), Frames of European program ERA-NET RUS PLUS., Université d'Orléans (UO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Soucé, Martin, Nanomédicaments et Nanosondes, EA 6295 ( NMNS ), Infectiologie Santé Publique ( ISP-311 ), Institut National de la Recherche Agronomique ( INRA ) -Université de Tours, Génétique, Immunothérapie, Chimie et Cancer ( GICC ), Université de Tours-Centre National de la Recherche Scientifique ( CNRS ), Centre de biophysique moléculaire ( CBM ), Université d'Orléans ( UO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry ( IBCh RAS ), Russian Academy of Sciences [Moscow] ( RAS ), and Lomonosov Moscow State University ( MSU )
- Subjects
[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,lcsh:Medical technology ,[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging ,Receptor, ErbB-2 ,lcsh:Biotechnology ,Magnetic Resonance Imaging (MRI) ,Contrast Media ,Mice, Nude ,Breast tumor ,Cyanine 5.5 ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Breast Neoplasms ,chemical and pharmacologic phenomena ,Ferric Compounds ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,Polyethylene Glycols ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,Cell Line, Tumor ,lcsh:TP248.13-248.65 ,Animals ,Humans ,Human Epithelial growth Receptor 2 (HER2) ,[SDV.IB.BIO]Life Sciences [q-bio]/Bioengineering/Biomaterials ,[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/Imaging ,Fluorescent Dyes ,[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,Research ,respiratory system ,[ SDV.IB.BIO ] Life Sciences [q-bio]/Bioengineering/Biomaterials ,Magnetic Resonance Imaging ,[SDV.IB.BIO] Life Sciences [q-bio]/Bioengineering/Biomaterials ,[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging ,lcsh:R855-855.5 ,Iron oxide nanoparticle ,Nanoparticles ,Female ,Single-Chain Antibodies ,Single chain variable fragment (scFv) - Abstract
Background Recent advances in nanomedicine have shown the great interest of active targeting associated to nanoparticles. Single chain variable fragments (scFv) of disease-specific antibodies are very promising targeting entities because they are small, not immunogenic and able to bind their specific antigens. The present paper is devoted to biological properties in vitro and in vivo of fluorescent and pegylated iron oxide nanoparticles (SPIONs-Cy-PEG-scFv) functionalized with scFv targeting Human Epithelial growth Receptor 2 (HER2). Results Thanks to a site-selective scFv conjugation, the resultant nanoprobes demonstrated high affinity and specific binding to HER2 breast cancer cells. The cellular uptake of SPIONs-Cy-PEG-scFv was threefold higher than that for untargeted PEGylated iron oxide nanoparticles (SPIONs-Cy-PEG) and is correlated to the expression of HER2 on cells. In vivo, the decrease of MR signals in HER2+ xenograft tumor is about 30% at 24 h after the injection. Conclusions These results all indicate that SPIONs-Cy-PEG-scFv are relevant tumor-targeting magnetic resonance imaging agents, suitable for diagnosis of HER2 overexpressing breast tumor. Electronic supplementary material The online version of this article (10.1186/s12951-018-0341-6) contains supplementary material, which is available to authorized users.
- Published
- 2018